CELGENE – CHMP Assessment Report: Negative for 1st-line Use and Maintenance Setting – Not Surprising!

Date: 2015-07
Pages:3
Price:

We hope that Celgene’s (CELG) 3Q12 result lift the gloom around news related to further delay (or no approval) of Revlimid in EU for Newly Diagnosed Multiple Myeloma (NDMM) /1st-line and maintenance setting. No ODAC panel meeting (earlier scheduled for Nov. 8, 2012) for Pomalidomide indirectly could reflect that there were no major safety issues. Clinical and regulatory news from Apremilast, ABRAXANE and Revlimid should keep the stock volatile…. For more detail please read our report released on 11th October, 2012 on CELG titled, “CHMP Assessment Report: Negative for 1st-line Use and Maintenance Setting – Not Surprising!”

Categories

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample